[Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome]

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and the leading cause of oligo/anovulatory infertility. The incidence of PCOS in the population is 5-10% depending on the phenotypic expression of the syndrome as use criteria for diagnosis Anti- Mullerian Hormone may be defined as a glycoprotein growth factor having autocrine and paracrine deystvie. Prodused in granulosa cells of the ovary and related to the growth and development of follicles. Studies devoted to the relationship between AMH and PCOS and hormone levels in the main phenotypes of PCOS are conflicting and few.

Objectives: Comparison of the serum levels of Anti-Mullerian Hormone (AMH) in major phenotypes of polycystic ovarian syndrome (A, B, C, D). As to study of correlation between serum levels of anti-Mullerian Hormone (AMH) and the other hormonal parameters

Design: Prospective comparative study.

Material and methods: Material and Methods. This study was conducted in the Department of Obstetrics and Gynecology, University Hospital St. George, Plovdiv and Clinic of Endocrinology, University Hospital St. George - Plovdiv. We studied 100 women aged between 18-35 years with polycystic ovary syndrome (PCOS) have been selected according to the criteria of the American Society of Reproductive Medicine (ASRM) - Rotterdam, 2003. Distributed by phenotypic characterization into four groups: Phenotype A (OA, HA and PCOS)--42 women; Phenotype B (OA and H)--23 women; Phenotype C (OA and PCOS)--20 women; Phenotype D (PCOS and OA)--15 women. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, androstenedione, estradiol (E2) and the Anti-Mullerian Hormone (AMH) are measured during the early follicular phase (day 3-5) of spontaneous menstrual cycle or progestin--induced uterine bleeding.

Results: Record the difference in the values of AMH in the main phenotypes subject of the study. We found different in strength and direction of correlations between the levels of AMH and other hormonal parameters studied.

Conclusion: These data on serum AMH levels in four major phenotypes of PCOS allow its use as an additional diagnostic criterion for diagnosis. Furthermore, differences in serum proven its level at the leading phenotypic expression may serve as a reliable tool to characterize the severity of the syndrome, monitoring and forecasting.